PSMAddition : essai de phase 3 comparant le traitement par 177Lu-PSMA-617 plus le standard de traitement (Sdt) versus le Sdt seul chez les patients CPHSm

Médecine Nucléaire - Tập 46 - Trang 77 - 2022
K. Fizazi1, R. Flippot1, S.T. Tagawa2, O. Sartor3, C. Parker4, F. Saad5, O. Sakharova6, J. De Bono7, F. Feng8, M.J. Morris9
1Gustave Roussy Institute, University of Paris Saclay, Villejuif
2Weill Cornell Medicine, New York, NY, USA
3Tulane Medical School, New Orleans, LA, USA
4The Royal Marsden Hospital, London, United Kingdom
5University of Montreal Hospital Center, Montreal, Quebec, Canada
6Advanced Accelerator Applications, A Novartis Company, Basel, Switzerland
7The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom
8University of California, San Francisco, SF, USA
9Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Thông tin
Thông tin xuất bản

Médecine Nucléaire

Tập 46

77

Thông tin tác giả